Homocysteine: Is it a clinically important cardiovascular risk factor?
Cleveland Clinic Journal of Medicine. 2004 September;71(9):729-734
September 1, 2004|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTElevated plasma homocysteine is associated with an increased risk of myocardial infarction, stroke, and venous thromboembolism. Folic acid and other B vitamins lower plasma homocysteine levels, but whether this therapy confers a clinical benefit has yet to be determined. Until we know the results of ongoing clinical trials of homocysteine-lowering therapy, testing for and treating elevated homocysteine is probably justified only in patients with known cardiovascular disease or who are at high risk.
